Answers are grounded in this paper and cite their sources.
A novel three-dimensional copper molybdate with mixed ligands, [[Cu(II)(2,2'-bpy)][Cu(II)(IN)(2)][Mo(4)O(12)(OH)(2)]] (IN(-) = isonicotinate ion, 2,2'-bpy = 2,2'-bipyridine), 1, has been hydrothermally synthesized and structurally characterized, and this compound is built from an unprecedented tetranuclear molybdenum oxide cluster covalently bonded to two types of copper complex fragments, [Cu(II)(2,2'-bpy)](2+) and [Cu(II)(IN)(2)], via terminal oxygen atoms of [MoO(6)] octahedra. Crystal data for compound 1: monoclinic, space group C2/c, a = 16.4755 A, b = 10.3714 A, c = 17.4382 A, alpha = 90.0000 degrees, beta = 94.8098 degrees, gamma = 90.0000 degrees; V = 2969.24 A(3); Z = 2. Variable temperature magnetic susceptibility indicates that both ferromagnetic and antiferromagnetic interactions exist in 1.
No takes yet. Share an insight, caveat, or question.
Lü et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: